Medtronic Plc is engaged in the medical technology-alleviating pain, restoring health, and extending life for millions of people around the world. Its customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. The company operates through four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group consist of three divisions : Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascular. The Minimally Invasive Technologies Group consists of two divisions: Surgical Solutions and Patient Monitoring and Recovery. The Restorative Therapies Group consists of four divisions: Spine, Neuromodulation, Surgical Technologies and Neurovascular. The Diabetes Group consists of three divisions: Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The company was founded on January 26, 2015 and is headquartered in Dublin, Ireland.
Once regarded as boring and fundamentally defensive, global healthcare stocks have re-emerged over the last few years as a powerhouse for future growth. Even though the S&P 500's healthcare sector is up over 20 per cent in the past year, it continues to offer more compelling entry points than its ASX-listed counterparts.
Given the strong run experienced by healthcare stocks globally, there are few – if any – absolute bargains left to pick off. Nevertheless, when you factor in their potential future upside, they still offer more compelling valuation propositions than their Aussie healthcare stocks. We found 9 future top performers in Skaffold Global.